Aripiprazole for Irritability Associated with Autistic Disorder in Children and Adolescents Aged 6–17 Years

Kelly Blankenship; Craig A Erickson; Kimberly A Stigler; David J Posey; Christopher J McDougle


Pediatr Health. 2010;4(4):375-381. 

In This Article

Future Perspective

It is likely that in the future, atypical antipsychotics will continue to be used to treat irritability in PDDs. Results from studies of aripiprazole reveal the possibility of significant weight gain in children, especially those younger than 12 years. Thus, there will likely be continued research of atypical antipsychotics to identify those with efficacy similar to risperidone and aripiprazole, but without severe side effects.

Long-term studies have not been published documenting aripiprazole's safety and efficacy for the treatment of irritability in the PDD population. These studies would help to provide evidence-based monitoring guidelines. This will likely be another focus of future research.

As there are currently only two FDA-approved medications for treatment of PDDs, aripiprazole remains a viable option to treat irritability in this population.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.